Date: 2012-10-04
Type of information: Development agreement
Compound: ARGX-109
Company: arGEN-X (The Netherlands-Belgium) RuiYi (formerly Anaphore) (USA-China)
Therapeutic area: Cancer - Oncology, Autoimmune diseases
Type agreement: development
licensing
commercialisation
Action mechanism:
Disease: cancer, autoimmune diseases
Details: arGEN-X has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. ARGX-109 is the first of five preclinical stage human antibody candidates developed by arGEN-X from its SIMPLE Antibody™ platform in the three years since its start of operations. ARGX-109 has outstanding neutralization potency for IL-6, a cytokine widely implicated in cancer and autoimmunity.
RuiYi is an american company focused on the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs). RuiYi’s executive management team has offices in La Jolla, CA while all of RuiYi’s discovery efforts are located in Shanghai, China. RuiYi’s research facility is located in the Zhangjiang Hi-Tech Park in Pudong Shanghai, China.
Financial terms: Under the agreement, RuiYi will make an upfront payment to arGEN-X consisting of cash and equity. arGEN-X is also eligible to receive additional payments based on the achievement of certain clinical, regulatory and commercialization milestones and royalties based on worldwide net sales of therapeutic products.
Latest news:
